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by dermatologists were more likely to receive surgery subsequently (p  0.002).
Older age and female gender were associated with a lower likelihood to receive
surgery, systemic, or radiation therapy. CONCLUSIONS: Sites of metastases and
treating physician specialty might influence treatments for patients with meta-
static melanoma.
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OBJECTIVES: To examine geographic variation and socio-demographic disparity in
the utilization of chemotherapy in patients with stage-III colon cancer, focusing
specifically on Oxaliplatin. METHODS: A retrospective cohort of 7654 Medicare
patients was identified from the Surveillance, Epidemiology and End Results –
Medicare linked database. Descriptive statistics show how Oxaliplatin containing
chemotherapy was utilized in various geographical regions, among different age
and racial groups. Multiple logistic regression was performed to examine the rela-
tionship between receipt of Oxaliplatin-containing chemotherapy and geographic
regionwhile adjusting for other socio-demographic and tumor characteristics. The
primary outcome of this study was the receipt of Oxaliplatin chemotherapy within
three to six month of colon-cancer specific surgery. RESULTS: Overall, only 51% of
the stage-III patients received adjuvant chemotherapy within 3 to 6 months of
colon-cancer specific surgery and it was evident that more patients in big metro
and metro regions used chemotherapy than patients in less-urban and rural re-
gions. Younger patients aged 66-70 yearsweremore likely to receive chemotherapy
than those of age 80 years and above; similarly, white patients were more likely to
receive chemotherapy compared to African-American population. The association
between the receipt of Oxaliplatin-containing chemotherapy and geographic re-
gions was not significant in univariate analysis; however, after controlling for the
confounding variables, it became statistically significant. Patients in the rural re-
gionswere approximately 30% less likely to receive Oxaliplatin chemotherapy than
those residing in bigmetro region (OR0.69, p0.033).CONCLUSIONS:Chemother-
apy use varies across geographic regions, especially for new chemotherapy drugs
like Oxaliplatin which in combination with 5-FU/LV is considered as standard ad-
juvant chemotherapy for use in patients with resected stage-III patients. Further
research is required to examine thoroughly the potential reasons behind this geo-
graphic disparity and find the ways to eliminate it in order to provide high-quality
cancer care to all patients.
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OBJECTIVES: This retrospective analysis of US hospital inpatient and outpatient
electronic records aimed to describe current blood transfusion utilization in a pop-
ulation with chemotherapy-induced anemia (CIA).METHODS: The Premier Hospi-
tal Database (2006-2010) was used to identify records for cancer patients aged 18
years or older who had received chemotherapy and a diagnosis of anemia (ICD9
codes: 284.x, 285.3, and 285.9). Excluded were those who received renal dialysis or
had a diagnosis of chronic kidney disease, myeloid cancer, myelodysplastic syn-
drome, or anemia due to chronic illnesses. The study population was then catego-
rized into three subgroups based on ICD-9 procedure codes, CPT codes, and billing
code descriptions in the database within the same month as or two months after
the anemia diagnosis: 1) The Blood Transfusion group had either ICD-9 codes, CPT
codes, or a select subset of billing code descriptions specific to blood transfusion; 2)
The Other/unknown Transfusion group had only billing code descriptions that
appeared to be transfusion-related but were non-specific; and 3) The No Transfu-
sion group had no transfusion-related ICD-9 codes, CPT codes, or billing code
descriptions. RESULTS: During the 5 years of data, there were 2980-7094 CIA oc-
currences in a given year. Average age for the CIA population ranged from 60-62
years and 52%-55%were female. During the years observed, the Blood Transfusion
group comprised 44-51% of the total CIA study population.When other transfusion
codes were considered (Blood Transfusion population plus Other/unknown Trans-
fusion population), this number increased to 56-61% of the total CIA study
population. CONCLUSIONS: These results from five years of hospital inpatient and
outpatient records suggest that there is a large portion of CIA patients that may be
receiving blood transfusions. Further research to better understand the character-
istics of CIA patients receiving blood transfusions and blood utilization in this
population is warranted.
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OBJECTIVES: Rapidly increasing use of imaging procedures in Canada and the
United States has raised concerns about exposure to low-dose ionizing radiation in
the general population. We assessed radiation exposure from medical and non-
medical uses. METHODS: Recent evidence-based studies linked exposure to low-
dose, ionizing radiation with the development of cancer/leukemia. Individuals at
risk for repeated radiation exposure (in health care/nuclear industry) are typically
monitored and restricted to effective doses of 20-50 mSv per year. In contrast,
radiation exposure in the general population is not monitored. Using the epidemi-
ological databases from Canada and the United States, we are developing an age/
sex stratified population model to assess radiation exposure from medical and
non-medical uses. We identify the potentially most exposed subpopulations, for
which the long-term risks are most relevant. RESULTS: We compiled the list of
effective doses (mSv) from radiation exposure for commonmedical and non-med-
ical uses, using National Council on Radiation Protection andMeasurement (NCRP)
data and other published sources. Excluding naturally occurring radiation, most of
radiation comes frommedical use as opposed to non-medical use. In medical use,
the bulk of exposure is related to CT and nuclear imaging, especially cardiac. Ex-
posure to nuclear medicine examinations among 65 individuals is 3 times higher
than among 30-44 group, fast growing over time, with higher exposure among
females than males. Concern is emerging about rapidly increasing doses among
pediatric populations. In non-medical use exposure is minor, coming mainly from
cigarette smoking, building materials, and commercial air travel. Results are pre-
sented by age and sex, and sensitivity analyses on selected variables are reported.
CONCLUSIONS: Given the rapidly growing radiation exposure, our findings might
have important implications for the health of the general population. Strategies to
monitor and to manage cumulative exposure, especially in medical use in the
general population should be developed.
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OBJECTIVES: To project the potential public health impact of a 9-valent HPV vac-
cine in the United States.METHODS:A previously published non-linear, determin-
istic compartmental model of HPV (6, 11, 16, and 18) transmission was extended to
include HPV 31, 33, 45, 52, and 58. We calibrated the model to US epidemiological
data on cervical cancer, attributing 70% of cervical cancer to HPV 16 and 18, and 20
% to HPV 31, 33, 45, 52, and 58. Other inputs were from public data sources and
published literature. Because it is currently unavailable, vaccine efficacy against 5
additional HPV types was assumed to be similar to that of the quadrivalent vaccine
(HPV4) against HPV 16.We assessed the impact of 9-valent HPV vaccination (HPV9)
relative to current US HPV4 recommendations, with routine vaccination for 11-12
year olds and a permanent catch-up program for 13–26 year old females and 13–18
year old males, and coverage of 80% for females and 48% for males, with 50% of
vaccinees receiving all doses of the vaccine. RESULTS: We project that HPV9 vac-
cination of males and females will reduce the incidence of cervical cancer by 63%
over 100 years, relative to 52% for HPV4. HPV9 vaccination relative to HPV 4 vacci-
nation prevents an additional 872,000 cases of CIN1 (Cervical Intraepithelial Neo-
plasia), 1,881,000 cases of CIN2/3, and 80,000 cases of cervical cancer in the US
population, cumulative over 100 years. CONCLUSIONS: Protecting the population
against HPV infection with an HPV9 vaccination program relative to an HPV4 vac-
cination program can have significant public health benefits.
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OBJECTIVES: This analysis evaluated whether health-related quality of life
(HRQOL) of patients newly diagnosed with active, symptomatic multiple myeloma
(MM) in the United States varies by their insurance coverage as they initiate
treatment.METHODS: Baseline data were collected in Connect® MM, a prospective
observational registry initiated in 2009. Clinicians provided data on patient demo-
graphics and clinical characteristics. Patients reported HRQOL in the clinic at en-
rollment within two months of diagnosis, by completing the Brief Pain Inventory
(BPI), EQ-5D, and Functional Assessment of Cancer Therapy-Multiple Myeloma
(FACT-MM). Patients were characterized by source of coverage: Medicare, Medic-
aid, Commercial-HMO/PPO, Other Commercial. The Medicare cohort included
those with supplemental coverage; the Medicaid cohort included dual Medicare-
Medicaid beneficiaries. Mean BPI, EQ-5D and FACT-MM scores were analyzed by
insurance coverage. Statistical significance was ascertained by ANOVA (SAS 9.1).
RESULTS: HRQOL data were reported by 1074 patients from 228 centers. Patients
were predominantly male (57%) and white (83%) with mean age 67 (standard devi-
ation 11) years. BPI data (on a scale of 0 [no pain] to 10 [worst pain] indicate that
average pain was less among HMO/PPO patients and worst among Medicaid pa-
tients (p0.0119). HMO/PPO patients fared better in the EQ-5D domain of mobility
than other cohorts (p0.0085), but no other statistically significant differences
were observed on EQ-5D scores (on a scale of 1 [no problem] to 2 [some problems] to
3 [incapacity]. FACT-G results indicate that Medicaid insurance is associated with
worse baseline HRQOL compared to other groups (p0.0229). CONCLUSIONS: Re-
sults from the Connect®MMRegistry suggest that certain HRQOL domains at treat-
ment initiation may be worse among Medicaid patients and better among HMO/
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PPOpatients compared to other groups. Future analyses should determinewhether
insurance coverage is associated with access to medical care and subsequent clin-
ical and HRQOL outcomes. These results serve as a baseline reference.
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OBJECTIVES: The use of administrative datasets can be a useful tool in cancer
surveillance by providing disease patterns, utilization of services, and patient char-
acteristics. This study explores characteristics of treatment and staging among
lung cancer patients in the US using hospital-based services. METHODS: A cross-
sectional study of chemotherapy treated lung cancer patients receiving in or out-
patient services from hospitals in MedAssets’ health data from July 1, 2010 to June
30, 2011 were assessed for staging and treatment characteristics. The Thomas, et
al. staging algorithm was applied to patient services to estimate stage of lung
cancer. Descriptive statistics were calculated for the sample by stage, treatment
characteristics, procedures and hospital characteristics. Patterns of care were tab-
ulated and compared by cancer stage. RESULTS: The sample included 14,628
unique patients who received chemotherapy during the study period spanning
over 217,000 hospital visits. The majority (75%) of hospital visits were classified as
stage 1-2 compared to stage 3-4 (25%). Stage 1-2 patients experienced fewer hospi-
tal visits (5.9 vs. 12.5, p 0.0001) and had a significantly higher proportion of inpa-
tient stays (22.1% vs. 6.7%, p 0.0001). Most visits (88.7%) occurred in hospital-
based outpatient facilities. There were 52,289 (3.1 visits per patient) chemotherapy
related visits. Primary chemotherapies included: pemetrexed disodium (16.2 %),
carboplatin (34.3%) and cisplatin (11.0%). Blood transfusions and other non-surgi-
cal procedures made up the largest portion (25.4%) of all procedures performed on
both groups. Finally, both groups were treated in primarily in large (300 beds,
75.1%), urban (90.1%), and teaching (59.1%) hospitals. CONCLUSIONS: The cross-
sectional analysis demonstrates the possible value of large-scale administrative
data sets in illuminating differences in treatment characteristic in a chemothera-
py-treated lung cancer population. Future analysis should evaluate the use of these
data to help predict utilization and treatment patterns in larger populations.
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OBJECTIVES: To describe treatment patterns by lines of systemic (drug) therapy in
patients with metastatic melanoma in the United States.METHODS: Using a large
USmedical claims database, patients were identified between 2005 and 2010 using
2 melanoma diagnoses (ICD-9-CM: 172.xx, V10.82) and 2 diagnoses for metas-
tasis (ICD-9-CM: 197.xx, 198.xx). Patients were followed from the metastatic diag-
nosis date to death, disenrollment, or end of study period (6/30/2010), whichever
occurred first. Lines of systemic therapy were identified based on the temporal
order, gaps, and changes in the drug regimens. Systemic therapies and the dura-
tion of therapy in each line were examined. RESULTS: A total of 2546 patients with
metastaticmelanomawere included and 985 (38.7%) received systemic therapy. As
the first documented therapy after diagnosis, 82.4% of patients received mono-
therapy (38.5% temozolomide, 14.3% interleukin-2, 11.4% interferon alfa-2b, 8.2%
dacarbazine, 2.9% paclitaxel, 2.5% GM-CSF) and 9.4% received carboplatin plus pa-
clitaxel. Mean duration of mono-therapy was 60 days, ranging from 32 days on
interleukin-2 to 124 days on GM-CSF. Of 287 patients (29.1% of previously treated)
received subsequent therapy, 68.0% received mono-therapy (26.8% temozolomide,
11.9% interleukin-2, 10.5% dacarbazine, 8.4% paclitaxel, 3.1% interferon alfa-2b,
1.7% GM-CSF), 16.7% carboplatin plus paclitaxel, and 7.3% dacarbazine-containing
therapies. Mean duration of mono-therapy was 67 days, ranging from 30 days on
interleukin-2 to 238 days on GM-CSF. Among 71 patients who further received
additional therapy, mono-therapy was still the dominant regimen (63.4%) with
21.1% temozolomide, 18.3% paclitaxel, 8.5% interleukin-2, 5.6% dacarbazine, 4.2%
GM-CSF, and 1.4% interferon alfa-2b. Carboplatin plus paclitaxelwas given to 19.7%
of patients. Mean duration of mono-therapy was 63 days, ranging from 7 days on
interferon alfa-2b to 90 days on temozolomide. CONCLUSIONS: The majority of
patients with advanced melanoma didn’t receive systemic therapy as captured in
the claims database; among those who received systemic therapy, mono-therapy
was most common.
PCN145
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OBJECTIVES: To identify treatment patterns of care in patients with unresectable
stage III or stage IV melanoma disease in three public hospitals in Mexico.
METHODS: Retrospective longitudinal study that includes 102 adult patients with
unresectable stage III (any T, N1, M0) or stage IV (any T, any N, M1) melanoma,
diagnosed and treated from 2007 to 2010, at three specialty public hospitals in
Mexico (Centro Médico Nacional Siglo XXI, Hospital General de Mexico and Insti-
tuto Nacional de Ciencias Médicas y Nutrición). Patient characteristics and re-
source utilization were reported for each stage of treatment (diagnosis, first line
treatment, and second line or palliative care) and includes consultations, labora-
tory tests, hospitalization, surgery, hematologic support, radiotherapy and sys-
temic treatment. RESULTS: The mean age at time of diagnosis was 60.44 years old
CI(56.88-64.00) and a men-women ratio of 1.17:1, 86% in clinical stage III and 14%
stage IV. The total cost of diagnosis was $15,628.10 CI($9,329.07-$21,927.14), which
includes: consultations $4,225.96 CI($3,423.20-$5,028.72), laboratory tests $5,930.40
CI($3,768.31-$8,092.49), and hospitalizations $5,471.74 CI($1,188.12-$9,755.37). Dur-
ing first line treatment, 44.9% of all cases report hospitalization, 21.8% radiother-
apy, 69.2% surgery and 76.9% systemic therapy (Dacarbazine 28.8%, Interferon-
66.1% and Temozolomide 5.1%), with a total cost of $76,162.57 ($64,771.54-
$87,553.59). Only 37.2% report a second line treatment, with a mean cost of
$25,816.83 CI($21,638.70-$29,994.97), the systemic treatment (monotherapy or
combined) included CDDP 11.5%, Dacarbazine 61.5%, Interferon- 19.2%, Paclitaxel
11.5%, Carboplatin 3.8% and Vinorelbine 3.8. CONCLUSIONS: In this study, 76.9% of
the patients received first line systemic treatment, and only 37.2% received a sec-
ond line active treatment or palliative care. The lack of active treatment could be
associated with a poor performance status in these patients, as well as a lack of
availability of effective drugs for the treatment of unresectable stage III or stage IV
melanoma in the public Mexican hospitals.
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OBJECTIVES: To explore physician specialty patterns for the treatment of hepato-
cellular carcinoma (HCC). METHODS: Medicare patients diagnosed with HCC in
2000-07 with1 claim for HCC-related physician visits post-diagnosis were stud-
ied through 2009 using SEER-Medicare data. Transplant patients were excluded.
Visits by specialists seenwithin 4weeks of diagnosis and by therapywithin the first
treatmentweekwere explored. Specialties: Gastroenterology (GE), General/Family/
Geriatric/Internal (GF), Diagnostic/Intervention radiology (DIR), Hematology/Med-
ical oncology (HMO), General surgery/Surgery oncology (GSO), Radiation oncology
(RO), Multispecialty clinic/group practice (MG), Others. Therapies (non-mutually
exclusive): surgical resection, percutaneous ablation, transarterial chemoemboli-
zation (TACE), bland embolization, systemic chemotherapy, selective internal ra-
diation therapy, external beam radiation therapy. We examined second-line ther-
apy, specialists seen since week 5, and multiple-specialty visits as related to
multiple-first-line therapies. RESULTS: Of 6472 patients with1 specialist, 25%
saw GE, 10.5%GF, 23% DIR, 28%HMO, 16% GSO, 4% RO, 5.5%MG, and 66%Other; 52%
saw1 specialist type within 4 weeks of diagnosis, 5%none until after 4 weeks; 6%
had a resection as first line, 8%ablation, 9%TACE, 0.7%TAE, 9%chemo, 1%SIRT,
8%EBRT; 64% were untreated; 46% of patients saw only 1 specialist type in the first
4 weeks and 4% got 1 therapy form in the first treatment week. The specialties
distributions did not differ across first-line therapies. Other specialists were seen
by 65% of patients. GE and HMO were the most common specialty: 21-29% of pa-
tients sawGE and 23-37% sawHMO, 20-24%DIR, 11-17%GSO, 9-13%GF, 4-6%RO, and
1%MG, across therapies. Of the 2819 patients who saw only 1 type of specialist in
the first 4 weeks, 52% visited Others, 13%GE, 11%HMO, 10%DIR, 6%GSO, 5%GF,
4%RO, and 0.4%MG. CONCLUSIONS: HCC patients commonly see Gastroenterolo-
gists and Hematologists/Medical oncologists within 4 weeks of HCC diagnosis.
There was no clear HCC treatment pattern by specialist type.
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OBJECTIVES: Observational data of chronic myelogenous leukemia (CML) patients
is difficult to obtain outside of a randomized clinical trial (RCT) setting. A retrospec-
tive research registry was developed to evaluate the outcomes of CML treatment
decisions.METHODS: The CML cohort was created through amaster patient index
(MPI) across the Huntsman Cancer Institute, University Hospital, and Outpatient
Clinics. Patient records (1995 – 2010) were included with CML ICD-9 codes (250.1,
205.10-12); age  18; a listing in the Utah Population Database; and chart review,
including physician notes and laboratory results, indicative of CML. RESULTS: A
total of 234 patients had confirmed CML (140 males, 59.8%). Mean age at diagnosis
was 46 (SD 15.1). Of those, 211 subjects (90.2%) were diagnosed in chronic phase
(CP), 12 (5.1%) in accelerated phase and 5 (2.1%) in blast phase (BP) with 15.5 (me-
dian; 14.6 mean, SD 4.2) CML cases diagnosed per year. Baseline lab results and
comorbidity scores were not statistically significantly different by stage, except for
an elevated platelet count in BP (p0.01). First line treatment was a tyrosine kinase
inhibitor for 51.3% overall, and 77.1% in new cases from 2001. Bone marrow trans-
plantwas utilized in 16.7%of patients overall. After 10 years, overall survival for the
CML cohort was 59.5%. Overall survival was 84.8% for patients diagnosed in CP and
treated with imatinib, 63.1% for patient’s receiving BMT and 41.4% for patients
treated with interferon-alpha. The most common cause of death overall was CML
(45.1%); in those receiving imatinib 38.9% died from CML. CONCLUSIONS: Clinical
outcomes data integrated via a MPI across a comprehensive research database to
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